Gossamer bio, inc. (GOSS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities
Net loss

-201,770

-180,307

-164,403

-165,305

-153,543

-146,969

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

1,077

917

759

633

460

297

0

0

0

Stock-based compensation expense

25,974

20,819

24,756

37,197

33,431

30,947

0

0

0

In process research and development expenses

5,405

3,600

2,000

10,261

29,761

49,659

0

0

0

Amortization of operating lease right-of-use assets

0

-

-

-

0

-

-

-

-

Amortization of long-term debt discount and issuance costs

0

-

-

-

-

-

-

-

-

Amortization of premium on investments, net of accretion of discounts

0

-

-

-

-

-

-

-

-

Net realized gain on investments

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

2,706

4,393

4,192

6,779

6,205

2,827

0

0

0

Other assets

-1,495

-2,714

-3,125

-2,747

-1,985

584

0

0

0

Operating lease liabilities

0

-

-

-

0

-

-

-

-

Accounts payable

-1,922

-1,399

-1,107

2,125

3,671

2,085

0

0

0

Accrued expenses

71

1,521

1,915

2,590

4,708

5,938

0

0

0

Accrued research and development expenses

4,072

8,605

11,267

12,579

12,725

10,527

0

0

0

Accrued compensation and benefits

1,116

5,180

0

0

0

-

-

-

0

Accrued interest expense

-

-

-

-

-

-117

0

0

0

Net cash used in operating activities

-169,355

-144,834

-125,717

-105,122

-75,110

-51,044

0

0

0

Cash flows from investing activities
Research and development asset acquisitions, net of cash acquired

5,405

3,600

2,000

10,261

29,897

17,721

0

0

0

Purchase of marketable securities

0

-

-

-

0

-

-

-

-

Maturities of marketable securities

0

-

-

-

0

-

-

-

-

Sales of marketable securities

0

-

-

-

0

-

-

-

-

Purchase of property and equipment

3,132

2,966

2,760

3,765

3,326

3,490

0

0

0

Net cash provided by (used in) investing activities

79,036

-147,144

-202,758

-325,823

-353,518

-144,711

0

0

0

Cash flows from financing activities
Proceeds from issuance of common stock

-

291,311

0

0

0

-

-

-

-

Proceeds from the exercise of stock options

1,989

2,045

0

0

0

-

-

-

-

Proceeds from issuance of convertible preferred stock, net

-

-

-

-

-

-

-

0

0

Repayment of notes payable to related parties

-

-

-

-

-

40

0

0

0

Net cash provided by financing activities

30,805

321,578

317,916

547,099

520,299

300,859

0

0

0

Effect of exchange rate changes on cash and cash equivalents

0

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-59,514

29,600

-10,559

116,154

91,671

105,104

0

0

0

Cash paid for interest

0

-

-

-

-

-

-

-

-

Supplemental disclosure of noncash investing and financing activities:
Acquisition of in-process research and development through issuance of stock

-

-

-

-

-

19,284

0

0

0

Issuance of Series A convertible preferred stock to convert debt and accrued interest

-

-

-

-

-

6,124

0

0

0

Right-of-use assets obtained in exchange for lease liabilities

-

-

-

-

0

-

-

-

-

Change in unrealized gain (loss) on marketable securities, net of tax

-485

331

0

0

0

-

-

-

-

Unpaid property and equipment

-496

183

0

0

0

-

-

-

0

Conversion of convertible preferred stock to common stock

-

338,367

0

0

0

-

-

-

-

Employee Stock Purchase Plan
Proceeds from issuance of common stock

0

-

-

-

-

-

-

-

-